SXC-2023
pharmaceutical compound
SXC-2023 is a cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator or glutamate modulator which is under development for the treatment of impulse control disorders such as trichotillomania (hair-pulling disorder). It is also being studied for treatment of cocaine-related disorders and smoking withdrawal. The drug is taken orally. The effects of SXC-2023 in animals have been studied. SXC-2023 was first described in the scientific literature by 2018. It was originated by Marquette University and the University of Wisconsin at Milwaukee and is under development by Promentis Pharmaceuticals and the National Institute on Drug Abuse (NIDA). As of June 2025, the drug is in phase 2 clinical trials.
The public source identifies “SXC-2023” as pharmaceutical compound. This brief keeps that definition visible, then builds a research path around SXC-2023, pharmaceutical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “SXC-2023”, the useful work is to connect “pharmaceutical compound” to the records capable of establishing context and consequence.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jan 29, 2026. The linked authority identifier is Q138132077. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2023, 2018 and 2025.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “SXC-2023”, its source revision and the description used here.
- Expand the search: follow SXC-2023 primary sources, SXC-2023 archive and SXC-2023 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “SXC-2023”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “SXC-2023” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.